SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    McCune JW. Cytotoxic drugs. In: WallaceDJ, HahnBH, editors. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins; 1997. p. 116380.
  • 2
    Marmont AM, van Lint MT, Gualandi F, Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 1997; 6: 5458.
  • 3
    Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 350514.
  • 4
    Illei GG, Klippel JH. Novel approaches in the treatment of lupus nephritis. Lupus 1998; 7: 6448.
  • 5
    Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, Durand-Gasselin I, et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 42130.
  • 6
    Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Morel Fourrier B, et al. In vivo production of interleukin-10 by non–T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37: 164755.
  • 7
    Hagiwara E, Gourley MF, Lee S, Klinman DM. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-γ–secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 37985.
  • 8
    Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Ohtsuka K, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998; 41: 83844.
  • 9
    Lacki JK, Samborski W, Mackiewicz SH. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 1997; 16: 2758.
  • 10
    Houssiau FA, Lefebvre C, van den Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 3935.
  • 11
    Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 2838.
  • 12
    Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine 1998; 10: 14853.
  • 13
    Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin 10 in the B-lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 83944.
  • 14
    De Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) strongly reduces antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down regulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 91524.
  • 15
    Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 122434.
  • 16
    Koppelman B, Neefjes JJ, de Vries JE, de Waal Malefyt R. Interleukin-10 down-regulates MHC class II ab peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997; 7: 86171.
  • 17
    Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long term antigen specific anergic state in human CD4+ T cells. J Exp Med 1996; 184: 1929.
  • 18
    Tsokos GC. Overview of cellular immune function in systemic lupus erythematosus. In: LahitaRG, editor. Systemic lupus erythematosus. New York: Academic Press; 1998. p. 1754.
  • 19
    Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, et al. A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 54929.
  • 20
    Huhn RD, Radwanski E, O'Connell SM, Sturgill MG, Clarke L, Cody RP, et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87: 699705.
  • 21
    Ishida H, Muchamuel S, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 30510.
  • 22
    Gladman DD, Urowitz MB. Prognostic subsets and mortality in systemic lupus erythematosus. In: WallaceDJ, HahnBH, editors. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins; 1997. p. 121327.
  • 23
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 24
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 25
    Guzmán J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus: prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 15518.
  • 26
    Lewkonia MR, Barth PT, Hale GM, Hughes GRV. Specificity and clinical relevance of antibodies to double-stranded DNA. Ann Rheum Dis 1977; 36 Suppl 1: 1148.
  • 27
    Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy: towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 1992; 22: 281924.
  • 28
    Brundula V, Rivas LJ, Blasini AM, París M, Salazar S, Stekman IL, et al. Diminished levels of T cell receptor ζ chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 190816.
  • 29
    Wong HK, Kammer GM, Dennis G, Tsokos GC. Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p62-RelA protein expression. J Immunol 1999; 163: 16829.
  • 30
    Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997; 100: 262233.
  • 31
    Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Ameisen JC. Th1/Th2 cytokines and T-cell death: preventive effect of IL-12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from HIV-infected persons. J Exp Med 1995; 182: 175967.
  • 32
    Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody independent role for B cells in murine lupus. J Exp Med 1999; 189: 163948.
  • 33
    Llorente L, Richaud-Patin Y, Couderc J, Alarcon-Segovia D, Ruiz-Soto R, Alcocer-Castillejos N, et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 142935.
  • 34
    Gröndal G, Kristjansdottir H, Gunnlaugsdottir B, Arnason A, Lundberg I, Klareskog L, et al. Increased number of interleukin-10–producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 1999; 42: 164954.
  • 35
    De Waal R, Malefyt W, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 120920.
  • 36
    Gérard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177: 54750.
  • 37
    Sironi M, Munoz C, Pollicino T, Siboni A, Sciacca FL, Bernasconi S, et al. Divergent effect of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells. Eur J Immunol 1993; 23: 26925.
  • 38
    Marfaing-Koka A, Maravic M, Humbert M, Galanaud P, Emilie D. Contrasting effects of IL4, IL-10 and corticosteroids on RANTES production by human monocytes. Intern Immunol 1996; 8: 158794.
  • 39
    Seitz M, Loetscher P, Dewald B, Towbin H, Gallati H, Baggiolini M. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol 1995; 25: 112932.
  • 40
    Marfaing-Koka A, Devergne O, Portier A, Schall TJ, Galanaud P, Emilie D. Regulation of the production of the chemokine RANTES by endothelial cells: synergistic induction by IFNgamma plus TNFalpha and inhibition by IL-4 and IL-13. J Immunol 1995; 154: 18708.
  • 41
    Chatelain R, Wollenberg A, Martin C, Panhans-Gross A, Heckmann M. IL-10 inhibits ICAM-1 expression on human Langerhans cells but not on keratinocytes, dermal endothelial cells or fibroblasts. Arch Dermatol Res 1998; 290: 47782.
  • 42
    Scholzen T, Hartmeyer M, Fastrich M, Brzoska T, Becher E, Schwarz T, et al. Ultraviolet light and interleukin-10 modulate expression of cytokines by transformed human dermal microvascular endothelial cells (HMEC-1). J Invest Dermatol 1998; 111: 506.
  • 43
    Krutmann J, Grewe M. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intracellular adhesion molecule-1 expression. J Invest Dermatol 1995; 105: 67S70S.
  • 44
    De Beaux AC, Maingay JP, Ross JA, Fearon KC, Carter DC. Interleukin-4 and interleukin-10 increase endotoxin stimulated human umbilical vein endothelial cell interleukin-8 release. J Interferon Cytokine Res 1995; 15: 4415.
  • 45
    Vora M, Romero LI, Karasek MA. Interleukin-10 induces E-selectin on small and large blood vessel endothelial cells. J Exp Med 1996; 184: 8219.
  • 46
    Wogensen L, Huang X, Sarvetnick N. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans. J Exp Med 1993; 178: 17585.
  • 47
    Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 84251.
  • 48
    Ullrich SE. Mechanism involved in the systemic suppression of antigen-presenting cell function by UV irradiation: keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells. J Immunol 1994; 152: 34106.
  • 49
    Grewe M, Gyufko K, Krutmann J. Interleukin-10 production by cultured human keratinocytes: regulation by ultraviolet B and ultraviolet A1 radiation. J Invest Dermatol 1995; 104: 36.